A French turkey multiplication company experienced a significant rise in Ornithobacterium rhinotracheale infections. Two clinical forms were observed: predominantly respiratory signs in the breeding farms (supplying the hatcheries) and joint/locomotor signs in the prebreeding farms (supplying breeding farms with 29-week-old future turkey layers). Repeated antibiotic treatments provided unsatisfactory results. As the birds’ welfare and performances were compromised, a broad herd-specific immunisation programme was designed, including 47 different vaccine formulations with one to four O rhinotracheale strains, in compliance with French regulations on autogenous vaccines. This programme was applied before the birds’ transfer in each of the affected prebreeding farms. Over the next two years, 63 batches were vaccinated; undesirable effects were not reported. Presence of O rhinotracheale was monitored in the receiving farms and occurred in 12 batches, two of which required antibiotic treatment. Control of O rhinotracheale was achieved through a customised immunisation programme, which has been maintained since.
- Ornithobacterium rhinotracheale
- autogenous vaccine
Statistics from Altmetric.com
Contributors CG was the main contributor to this manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.